Should You Sell Maravai LifeSciences (MRVI)?
ClearBridge Investments, an investment management firm, released its fourth-quarter 2023 “Mid Cap Strategy” investor letter, which can be downloaded here.
Maravai Lifesciences Holdings Inc. (MRVI)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 12 West Capital Management Joel Ramin | 11,602,988 | $75,999,571 | +80% | 6.76% |
| 2. | Millennium Management Israel Englander | 5,786,849 | $37,903,861 | +36% | 0.01% |
| 3. | Braidwell LP Alex Karnal | 5,040,635 | $33,016,159 | +27% | 1.21% |
| 4. | AQR Capital Management Cliff Asness | 3,504,111 | $22,951,927 | +101% | 0.04% |
| 5. | Alyeska Investment Group Anand Parekh | 3,196,489 | $20,937,003 | +34% | 0.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.94 | 35,000 | Officer, Director | 35,000 | 2020-11-25 | Filing | |
| $27.00 | 20,000 | Director | 31,852 | 2020-11-24 | Filing | |
| $27.00 | 18,888 | Officer | 18,888 | 2020-11-24 | Filing | |
| $27.00 | 10,000 | Director | 21,852 | 2020-11-24 | Filing | |
| $27.00 | 18,000 | Director | 29,852 | 2020-11-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 21,681,033 | $142,010,766 | 8.61% | |
| 2. | 10,003,894 | $65,525,506 | 0% | |
| 3. | 6,481,668 | $42,454,926 | 0% | |
| 4. | 6,014,575 | $39,395,465 | 0.01% | |
| 5. | 5,169,176 | $33,858,103 | 0.05% |
News See All
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q4 2023 Earnings Call Transcript
Operator: Good afternoon and thank you for standing by. At this time, we would like to welcome everyone to the Q4 2023 Maravai LifeSciences Earnings Conference Call.
Will Maravai LifeSciences Holdings (MRVI) Pipeline Start to Bear Fruit?
Baron Funds, an investment management company, released its “Baron Discovery Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. My name is Tammy and I will be your conference operator today.
12 Cheap Biotech Stocks Smart Investors Are Piling Into
In this piece, we will take a look at 12 cheap biotechnology stocks that smart investors are piling into.
25 Biggest Stocks with Negative Beta
Stock markets were in see-saw mode before the Fed’s September decision on rate hikes.
11 Most Undervalued Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 11 most undervalued biotech stocks to buy according to analysts.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q2 2023 Earnings Call Transcript
Operator: Thank you for standing by. I would like to welcome everyone to the Quarter Two 2023 Maravai LifeSciences' Earnings Conference Call.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q1 2023 Earnings Call Transcript
Operator: Good afternoon. My name is Rob, and I will be your conference operator today.